NKTR · Categories · Form 4

NKTR - SEC Form 4 insider transactions

Nektar Therapeutics (NKTR) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for NKTR

• 19d
  Chief R&D Officer Zalevsky Jonathan sold $13,036 worth of shares (199 units at $65.51), decreasing direct ownership by 0.94% to 20,975 units (SEC Form 4) (withholding tax)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 19d
  President & CEO Robin Howard W sold $29,086 worth of shares (444 units at $65.51), decreasing direct ownership by 0.59% to 75,045 units (SEC Form 4) (tax withholding)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 109d
  Chief R&D Officer Zalevsky Jonathan sold $13,140 worth of shares (180 units at $73.00), decreasing direct ownership by 0.84% to 21,174 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 109d
  President & CEO Robin Howard W sold $30,879 worth of shares (423 units at $73.00), decreasing direct ownership by 0.56% to 75,489 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 138d
  Chief R&D Officer Zalevsky Jonathan sold $137,936 worth of shares (3,867 units at $35.67), decreasing direct ownership by 15% to 21,354 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 168d
  Chief R&D Officer Zalevsky Jonathan was granted 6,250 shares, increasing direct ownership by 33% to 25,221 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 168d
  President & CEO Robin Howard W was granted 21,667 shares, increasing direct ownership by 40% to 75,912 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 196d
  Chief R&D Officer Zalevsky Jonathan was granted 2,666 shares and sold $62,802 worth of shares (1,157 units at $54.28), increasing direct ownership by 9% to 18,971 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 196d
  Chief Legal Officer Wilson Mark Andrew sold $34,196 worth of shares (630 units at $54.28) and was granted 1,903 shares, increasing direct ownership by 6% to 21,585 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 196d
  President & CEO Robin Howard W was granted 7,110 shares and sold $119,796 worth of shares (2,207 units at $54.28), increasing direct ownership by 10% to 54,245 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 251d
  SEC Form 4 filed by Director Whitfield Roy A

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 251d
  SEC Form 4 filed by Director Greer R Scott

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 251d
  SEC Form 4 filed by Director Chess Robert

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 251d
  SEC Form 4 filed by Director Brainard Diana

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 251d
  SEC Form 4 filed by Director Ajer Jeffrey Robert

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 271d
  President & CEO Robin Howard W sold $311,214 worth of shares (6,666 units at $46.69), decreasing direct ownership by 12% to 49,342 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 274d
  Chief R&D Officer Zalevsky Jonathan sold $57,693 worth of shares (1,721 units at $33.52), decreasing direct ownership by 9% to 17,462 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 274d
  President & CEO Robin Howard W sold $430,959 worth of shares (11,832 units at $36.42), decreasing direct ownership by 17% to 56,008 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 278d
  Chief R&D Officer Zalevsky Jonathan sold $14,598 worth of shares (485 units at $30.10), decreasing direct ownership by 2% to 19,183 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 278d
  President & CEO Robin Howard W sold $45,240 worth of shares (1,500 units at $30.16), decreasing direct ownership by 2% to 67,840 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 292d
  Chief R&D Officer Zalevsky Jonathan sold $19,278 worth of shares (725 units at $26.59), decreasing direct ownership by 4% to 19,668 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 292d
  Chief Legal Officer Wilson Mark Andrew sold $17,975 worth of shares (676 units at $26.59), decreasing direct ownership by 3% to 20,312 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 292d
  President & CEO Robin Howard W sold $41,826 worth of shares (1,573 units at $26.59), decreasing direct ownership by 2% to 69,340 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 384d
  Chief R&D Officer Zalevsky Jonathan sold $7,177 worth of shares (10,712 units at $0.67), decreasing direct ownership by 3% to 305,892 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 384d
  Chief Legal Officer Wilson Mark Andrew sold $6,697 worth of shares (9,996 units at $0.67), decreasing direct ownership by 3% to 314,296 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 384d
  President & CEO Robin Howard W sold $15,549 worth of shares (23,208 units at $0.67), decreasing direct ownership by 2% to 1,063,693 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 473d
  Chief R&D Officer Zalevsky Jonathan sold $10,403 worth of shares (10,300 units at $1.01), decreasing direct ownership by 3% to 316,604 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 473d
  Chief Legal Officer Wilson Mark Andrew sold $11,150 worth of shares (11,040 units at $1.01), decreasing direct ownership by 3% to 324,292 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 473d
  President & CEO Robin Howard W sold $24,012 worth of shares (23,774 units at $1.01), decreasing direct ownership by 2% to 1,086,901 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 530d
  Chief Legal Officer Wilson Mark Andrew sold $44,800 worth of shares (49,962 units at $0.90), decreasing direct ownership by 13% to 335,332 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 536d
  Chief R&D Officer Zalevsky Jonathan sold $48,048 worth of shares (51,115 units at $0.94), decreasing direct ownership by 14% to 326,904 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 537d
  President & CEO Robin Howard W sold $131,650 worth of shares (132,030 units at $1.00), decreasing direct ownership by 11% to 1,110,675 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 539d
  Chief R&D Officer Zalevsky Jonathan was granted 135,000 shares, increasing direct ownership by 56% to 378,019 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 539d
  Chief Legal Officer Wilson Mark Andrew was granted 165,938 shares, increasing direct ownership by 76% to 385,294 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 539d
  President & CEO Robin Howard W was granted 410,625 shares, increasing direct ownership by 49% to 1,242,705 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 566d
  Chief R&D Officer Zalevsky Jonathan sold $7,863 worth of shares (7,785 units at $1.01), decreasing direct ownership by 3% to 243,019 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 566d
  Chief Legal Officer Wilson Mark Andrew sold $6,471 worth of shares (6,407 units at $1.01), decreasing direct ownership by 3% to 218,856 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 566d
  President & CEO Robin Howard W sold $16,441 worth of shares (16,278 units at $1.01), decreasing direct ownership by 2% to 832,080 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 658d
  Chief R&D Officer Zalevsky Jonathan sold $8,788 worth of shares (6,866 units at $1.28), decreasing direct ownership by 3% to 250,804 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 658d
  Chief Legal Officer Wilson Mark Andrew sold $7,233 worth of shares (5,651 units at $1.28), decreasing direct ownership by 2% to 225,263 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 658d
  President & CEO Robin Howard W sold $19,048 worth of shares (14,881 units at $1.28), decreasing direct ownership by 2% to 848,358 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 725d
  Director Chess Robert sold $23,400 worth of shares (19,500 units at $1.20), decreasing direct ownership by 7% to 255,273 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 750d
  Robin Howard W sold $29,138 worth of shares (16,650 units at $1.75), decreasing direct ownership by 2% to 863,239 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 750d
  Zalevsky Jonathan sold $12,871 worth of shares (7,355 units at $1.75), decreasing direct ownership by 3% to 257,670 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 750d
  Wilson Mark Andrew sold $10,955 worth of shares (6,260 units at $1.75), decreasing direct ownership by 3% to 230,414 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 757d
  Deep Track Capital, Lp sold $99,630 worth of shares (56,000 units at $1.78) (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 838d
  Zalevsky Jonathan sold $6,130 worth of shares (9,014 units at $0.68), decreasing direct ownership by 3% to 265,025 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 838d
  Wilson Mark Andrew sold $5,172 worth of shares (7,606 units at $0.68), decreasing direct ownership by 3% to 236,674 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 838d
  Robin Howard W sold $13,622 worth of shares (20,033 units at $0.68), decreasing direct ownership by 2% to 879,889 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 907d
  SEC Form 4 filed by Zalevsky Jonathan

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 907d
  SEC Form 4 filed by Wilson Mark Andrew

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 907d
  SEC Form 4 filed by Robin Howard W

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 932d
  Zalevsky Jonathan sold $4,727 worth of shares (9,646 units at $0.49), decreasing direct ownership by 3% to 274,039 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 932d
  Wilson Mark Andrew sold $3,518 worth of shares (7,179 units at $0.49), decreasing direct ownership by 3% to 243,780 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 932d
  Robin Howard W sold $9,740 worth of shares (19,877 units at $0.49), decreasing direct ownership by 2% to 899,922 units (SEC Form 4)

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 992d
  SEC Form 4 filed by Greer R Scott

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 993d
  SEC Form 4 filed by Whitfield Roy A

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 993d
  SEC Form 4: Curet Myriam sold $3,008 worth of shares (4,359 units at $0.69), decreasing direct ownership by 14% to 27,418 units

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 993d
  SEC Form 4: Chess Robert sold $6,834 worth of shares (10,200 units at $0.67), decreasing direct ownership by 4% to 274,773 units

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
• 993d
  SEC Form 4 filed by Brainard Diana

  4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

Other NKTR categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends